How AAV Gene Transfer Works - General Audience

Поделиться
HTML-код
  • Опубликовано: 7 окт 2024
  • This brief animation, designed for a general audience, illustrates the basics of AAV gene transfer technology.

Комментарии • 16

  • @XxSolvexX
    @XxSolvexX 4 года назад +5

    Exceptional animations. Amazing how seeing it like this really settles in the feeling of just how incredible this technology is to manipulate our already unbelievable physiological mechanisms

  • @shayanghafary6857
    @shayanghafary6857 2 года назад

    the animations here are insane! Thank you, very useful to see the whole process animated like this, very educational. helps understand.

  • @chittaranjanpal8950
    @chittaranjanpal8950 6 лет назад +6

    thats the beauty of molecular biology...i am in love ...😍😍

  • @juanpabloparzela
    @juanpabloparzela 6 лет назад +5

    Magnificent video. Thank you UniQure!!

  • @lnagel-good-life-templates
    @lnagel-good-life-templates 5 лет назад +4

    Great video! Very well portrayed.

  • @nzehavi
    @nzehavi 3 года назад +1

    what an amazing animation!!!!

  • @mdshahidulislam6805
    @mdshahidulislam6805 5 лет назад +4

    Smart animation.

  • @nayeemahmed9440
    @nayeemahmed9440 5 лет назад +2

    thanks

  • @jacklynallen7549
    @jacklynallen7549 3 года назад +1

    Does anyone know what company produced this animation?!

  • @angadmahanta8807
    @angadmahanta8807 7 лет назад +3

    Animation😮

  • @learningpower9437
    @learningpower9437 3 года назад

    Excellent video .... !!!! If m-RNA is formed from the transcription of the DNA episome ... what will happen when the cells that have the episomes die ...? .... Do we have to re-inject the patient ...? ... But you will need a different adenovirus ... because for the first one ... the body will have a strong immune response to it ... Maybe a retrovirus ... will solve the problem ...

    • @underzepump2905
      @underzepump2905 2 года назад

      Regarding your first question: this depends on the target cells. Trials are in place in a number of therapy areas looking at duration of response. Presumably, if the response wanes after a period, another injection or infusion would be required... Which brings us to the next question - will the same AAV work again, even when the patient has neutralising antibodies? Some trials are looking at this, and it looks like the answer is "it depends" at the moment (on which AAV serotype is used, the individual patient and their pre-existing neutralising antibodies, and what level of response is expected/desired).

  • @life_2022
    @life_2022 2 года назад

    it forms episome like a second DNA not integrated cells own DNA if there is a missing gene it may work but if cells own DNA produce faulty protein or wrong protein it is going to build up in body episome will create right protein and at he same time cell's own dna will create wrong protein both

  • @nirvananagi
    @nirvananagi 6 лет назад +2

    this is LIIT

  • @Wheres-my-toes-bro
    @Wheres-my-toes-bro Год назад

    1:35 instead of a therapeutic molecule imagine it produces a cytotoxic synthetic protein that triggers inflammatory responses and autoimmune issues and no long term data on effects.